Orlistat

Orlistat

• CAS Number: 96829-58-2
• UNSPSC Description: Orlistat (Tetrahydrolipstatin) is a well-known irreversible inhibitor of pancreatic and gastric lipases. Orlistat is also an inhibitor of fatty acid synthase (FASN), is used orally for long-term research of obesity[1]. Anti-atherosclerotic effect[2].
• Target Antigen: Apoptosis; Fatty Acid Synthase (FASN)
• Type: Reference compound
• Related Pathways: Apoptosis;Metabolic Enzyme/Protease
• Applications: Cancer-programmed cell death
• Field of Research: Metabolic Disease; Cancer
• Assay Protocol: https://www.medchemexpress.com/orlistat.html
• Purity: 99.97
• Solubility: DMSO : 100 mg/mL (ultrasonic)|H2O : < 0.1 mg/mL
• Smiles: O=C1[C@@H](CCCCCC)[C@H](C[C@@H](OC([C@@H](N([H])C([H])=O)CC(C)C)=O)CCCCCCCCCCC)O1
• Molecular Weight: 495.73
• References & Citations: [1]Giorgia Cioccoloni, et al. Influence of fatty acid synthase inhibitor orlistat on the DNA repair enzyme O6-methylguanine-DNA methyltransferase in human normal or malignant cells in vitro. Int J Oncol. 2015 Aug;47(2):764-72.|[2]Zaidatul Akmal Othman, et al. Anti-Atherogenic Effects of Orlistat on Obesity-Induced Vascular Oxidative Stress Rat Model. Antioxidants (Basel). 2021 Feb 6;10(2):251.
• Shipping Conditions: Room Temperature
• Storage Conditions: -20°C, 3 years; 4°C, 2 years (Powder)
• Clinical Information: Launched